Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex®
| ISSN: |
1432-1041
|
|---|---|
| Keywords: |
PDX chloride ; cholesterol ; clofibrate ; hyperlipoproteinaemia type II ; bile acid sequestrant
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Chemistry and Pharmacology
Medicine
|
| Notes: |
Summary Eleven patients with hyperlipoproteinaemia type II A, who were relatively resistant to hypolipidaemic drugs, were treated for four to six months with an anion exchange resin, Secholex® (PDX chloride), 15 g per day. The mean monthly plasma cholesterol level decreased by 10–18% (p〈0.01 andp〈0.001 respectively) from its pre-treatment value of 431±50 mg/100 ml (mean ±95% confidence limits). The reduction of plasma cholesterol was due mainly to a decrease in low density lipoproteins (LDL) of 50 mg/100 ml (p〈0.01). Very low density lipoproteins (VLDL) were moderately (p〈0.05) reduced and high density lipoproteins (HDL) remained unchanged. The mean pretreatment plasma triglyceride level (110±30 mg/100 ml) did not alter significantly. Nine of the patients had previously received clofibrate and in them Secholex reduced plasma cholesterol by 17% and clofibrate by 6%. Excluding one patient on clofibrate who had an unexpected increase in plasma cholesterol, there was little difference between the efficacy of clofibrate and Secholex. After four months two patients withdrew from the trial because of constipation. There was slight transient increase in mean serum alkaline phosphatase and a decrease in serum uric acid during treatment with Secholex.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798295571474153474 |
|---|---|
| autor | Gustafson, A. Lanner, Å. |
| autorsonst | Gustafson, A. Lanner, Å. |
| book_url | http://dx.doi.org/10.1007/BF00614393 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM202483231 |
| issn | 1432-1041 |
| journal_name | European journal of clinical pharmacology |
| materialart | 1 |
| notes | Summary Eleven patients with hyperlipoproteinaemia type II A, who were relatively resistant to hypolipidaemic drugs, were treated for four to six months with an anion exchange resin, Secholex® (PDX chloride), 15 g per day. The mean monthly plasma cholesterol level decreased by 10–18% (p〈0.01 andp〈0.001 respectively) from its pre-treatment value of 431±50 mg/100 ml (mean ±95% confidence limits). The reduction of plasma cholesterol was due mainly to a decrease in low density lipoproteins (LDL) of 50 mg/100 ml (p〈0.01). Very low density lipoproteins (VLDL) were moderately (p〈0.05) reduced and high density lipoproteins (HDL) remained unchanged. The mean pretreatment plasma triglyceride level (110±30 mg/100 ml) did not alter significantly. Nine of the patients had previously received clofibrate and in them Secholex reduced plasma cholesterol by 17% and clofibrate by 6%. Excluding one patient on clofibrate who had an unexpected increase in plasma cholesterol, there was little difference between the efficacy of clofibrate and Secholex. After four months two patients withdrew from the trial because of constipation. There was slight transient increase in mean serum alkaline phosphatase and a decrease in serum uric acid during treatment with Secholex. |
| package_name | Springer |
| publikationsjahr_anzeige | 1974 |
| publikationsjahr_facette | 1974 |
| publikationsjahr_intervall | 8029:1970-1974 |
| publikationsjahr_sort | 1974 |
| publisher | Springer |
| reference | 7 (1974), S. 65-69 |
| schlagwort | PDX chloride cholesterol clofibrate hyperlipoproteinaemia type II bile acid sequestrant |
| search_space | articles |
| shingle_author_1 | Gustafson, A. Lanner, Å. |
| shingle_author_2 | Gustafson, A. Lanner, Å. |
| shingle_author_3 | Gustafson, A. Lanner, Å. |
| shingle_author_4 | Gustafson, A. Lanner, Å. |
| shingle_catch_all_1 | Gustafson, A. Lanner, Å. Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® PDX chloride cholesterol clofibrate hyperlipoproteinaemia type II bile acid sequestrant PDX chloride cholesterol clofibrate hyperlipoproteinaemia type II bile acid sequestrant Summary Eleven patients with hyperlipoproteinaemia type II A, who were relatively resistant to hypolipidaemic drugs, were treated for four to six months with an anion exchange resin, Secholex® (PDX chloride), 15 g per day. The mean monthly plasma cholesterol level decreased by 10–18% (p〈0.01 andp〈0.001 respectively) from its pre-treatment value of 431±50 mg/100 ml (mean ±95% confidence limits). The reduction of plasma cholesterol was due mainly to a decrease in low density lipoproteins (LDL) of 50 mg/100 ml (p〈0.01). Very low density lipoproteins (VLDL) were moderately (p〈0.05) reduced and high density lipoproteins (HDL) remained unchanged. The mean pretreatment plasma triglyceride level (110±30 mg/100 ml) did not alter significantly. Nine of the patients had previously received clofibrate and in them Secholex reduced plasma cholesterol by 17% and clofibrate by 6%. Excluding one patient on clofibrate who had an unexpected increase in plasma cholesterol, there was little difference between the efficacy of clofibrate and Secholex. After four months two patients withdrew from the trial because of constipation. There was slight transient increase in mean serum alkaline phosphatase and a decrease in serum uric acid during treatment with Secholex. 1432-1041 14321041 Springer |
| shingle_catch_all_2 | Gustafson, A. Lanner, Å. Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® PDX chloride cholesterol clofibrate hyperlipoproteinaemia type II bile acid sequestrant PDX chloride cholesterol clofibrate hyperlipoproteinaemia type II bile acid sequestrant Summary Eleven patients with hyperlipoproteinaemia type II A, who were relatively resistant to hypolipidaemic drugs, were treated for four to six months with an anion exchange resin, Secholex® (PDX chloride), 15 g per day. The mean monthly plasma cholesterol level decreased by 10–18% (p〈0.01 andp〈0.001 respectively) from its pre-treatment value of 431±50 mg/100 ml (mean ±95% confidence limits). The reduction of plasma cholesterol was due mainly to a decrease in low density lipoproteins (LDL) of 50 mg/100 ml (p〈0.01). Very low density lipoproteins (VLDL) were moderately (p〈0.05) reduced and high density lipoproteins (HDL) remained unchanged. The mean pretreatment plasma triglyceride level (110±30 mg/100 ml) did not alter significantly. Nine of the patients had previously received clofibrate and in them Secholex reduced plasma cholesterol by 17% and clofibrate by 6%. Excluding one patient on clofibrate who had an unexpected increase in plasma cholesterol, there was little difference between the efficacy of clofibrate and Secholex. After four months two patients withdrew from the trial because of constipation. There was slight transient increase in mean serum alkaline phosphatase and a decrease in serum uric acid during treatment with Secholex. 1432-1041 14321041 Springer |
| shingle_catch_all_3 | Gustafson, A. Lanner, Å. Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® PDX chloride cholesterol clofibrate hyperlipoproteinaemia type II bile acid sequestrant PDX chloride cholesterol clofibrate hyperlipoproteinaemia type II bile acid sequestrant Summary Eleven patients with hyperlipoproteinaemia type II A, who were relatively resistant to hypolipidaemic drugs, were treated for four to six months with an anion exchange resin, Secholex® (PDX chloride), 15 g per day. The mean monthly plasma cholesterol level decreased by 10–18% (p〈0.01 andp〈0.001 respectively) from its pre-treatment value of 431±50 mg/100 ml (mean ±95% confidence limits). The reduction of plasma cholesterol was due mainly to a decrease in low density lipoproteins (LDL) of 50 mg/100 ml (p〈0.01). Very low density lipoproteins (VLDL) were moderately (p〈0.05) reduced and high density lipoproteins (HDL) remained unchanged. The mean pretreatment plasma triglyceride level (110±30 mg/100 ml) did not alter significantly. Nine of the patients had previously received clofibrate and in them Secholex reduced plasma cholesterol by 17% and clofibrate by 6%. Excluding one patient on clofibrate who had an unexpected increase in plasma cholesterol, there was little difference between the efficacy of clofibrate and Secholex. After four months two patients withdrew from the trial because of constipation. There was slight transient increase in mean serum alkaline phosphatase and a decrease in serum uric acid during treatment with Secholex. 1432-1041 14321041 Springer |
| shingle_catch_all_4 | Gustafson, A. Lanner, Å. Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® PDX chloride cholesterol clofibrate hyperlipoproteinaemia type II bile acid sequestrant PDX chloride cholesterol clofibrate hyperlipoproteinaemia type II bile acid sequestrant Summary Eleven patients with hyperlipoproteinaemia type II A, who were relatively resistant to hypolipidaemic drugs, were treated for four to six months with an anion exchange resin, Secholex® (PDX chloride), 15 g per day. The mean monthly plasma cholesterol level decreased by 10–18% (p〈0.01 andp〈0.001 respectively) from its pre-treatment value of 431±50 mg/100 ml (mean ±95% confidence limits). The reduction of plasma cholesterol was due mainly to a decrease in low density lipoproteins (LDL) of 50 mg/100 ml (p〈0.01). Very low density lipoproteins (VLDL) were moderately (p〈0.05) reduced and high density lipoproteins (HDL) remained unchanged. The mean pretreatment plasma triglyceride level (110±30 mg/100 ml) did not alter significantly. Nine of the patients had previously received clofibrate and in them Secholex reduced plasma cholesterol by 17% and clofibrate by 6%. Excluding one patient on clofibrate who had an unexpected increase in plasma cholesterol, there was little difference between the efficacy of clofibrate and Secholex. After four months two patients withdrew from the trial because of constipation. There was slight transient increase in mean serum alkaline phosphatase and a decrease in serum uric acid during treatment with Secholex. 1432-1041 14321041 Springer |
| shingle_title_1 | Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® |
| shingle_title_2 | Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® |
| shingle_title_3 | Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® |
| shingle_title_4 | Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:38:19.269Z |
| titel | Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® |
| titel_suche | Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® |
| topic | V WW-YZ |
| uid | nat_lic_papers_NLM202483231 |